Evaluation and Management of Elevated GGT and CRP
When a patient presents with elevated gamma-glutamyl transferase (GGT) and C-reactive protein (CRP), the primary focus should be on comprehensive liver disease evaluation, as GGT elevation signals potential hepatic pathology that requires systematic investigation regardless of the CRP elevation. 1
Initial Laboratory Assessment
Obtain a complete liver blood test panel immediately, including:
- Bilirubin, albumin, ALT, ALP, and GGT (if not already done)
- Full blood count
- AST to calculate the AST:ALT ratio 1
The AST:ALT ratio is critical even when both values are within normal range—a ratio >1 indicates advanced fibrosis or cirrhosis and necessitates urgent specialist referral. 1
Extended Liver Etiology Screen
Proceed with a comprehensive liver etiology panel to identify treatable causes:
- Viral hepatitis: Hepatitis B surface antigen and hepatitis C antibody with reflex PCR if positive 1
- Iron overload: Ferritin and transferrin saturation 1
- Autoimmune liver disease: Anti-mitochondrial antibody, anti-smooth muscle antibody, antinuclear antibody, serum immunoglobulins, anti-LKM antibody 1
- Metabolic conditions: Alpha-1-antitrypsin level, thyroid function tests, ceruloplasmin (if age 3-40 years) 1
Risk Factor Assessment
Evaluate for the two most common causes of liver disease—NAFLD and alcohol-related liver disease (ARLD)—which account for 90% of liver mortality: 1
Alcohol Assessment
- Administer AUDIT-C screening followed by full 10-item AUDIT 1
- AUDIT score >19 indicates alcohol dependency requiring referral to alcohol services 1
- For harmful drinkers (≥50 units/week men, ≥35 units/week women), perform Fibroscan/ARFI elastography 1
- If GGT >100 U/L, strongly consider fibrosis assessment even at lower alcohol intake 1
NAFLD Risk Factors
Assess for:
- Type 2 diabetes mellitus
- BMI >25
- Dyslipidemia
- Hypertension 1
Note the synergistic effect: when BMI >35, the risk of liver disease doubles for any given alcohol intake. 1
Fibrosis Risk Stratification
Calculate non-invasive fibrosis scores (FIB-4, NFS, or ELF) to assess disease severity 1
Refer to gastroenterology/hepatology if:
- Fibroscan reading >16 kPa 1
- Features of cirrhosis or portal hypertension on imaging or blood tests 1
- Persistently elevated liver enzymes with negative extended etiology screen and no NAFLD risk factors 1
- AST:ALT ratio >1 1
Understanding the CRP Elevation
CRP >10 mg/L does not automatically indicate acute infection—multiple factors can elevate CRP chronically: 2
- Obesity
- Smoking
- Sedentary lifestyle
- Heritable factors
- Chronic inflammatory conditions 2
The combination of elevated GGT and CRP is particularly concerning as these markers are synergistically associated with:
- Metabolic syndrome and insulin resistance 3, 4
- Increased cardiovascular risk 5, 6, 7
- Poor glycemic control in diabetic patients 8
- Coronary plaque burden and severity 5, 9
Cardiovascular Risk Assessment
Given the synergistic relationship between GGT and CRP, assess cardiovascular risk factors:
- Blood pressure (both markers correlate with hypertension) 6
- Lipid profile (GGT correlates with triglycerides and inversely with HDL) 8, 3
- Fasting glucose and HbA1c 8, 3
- Waist circumference (CRP correlates strongly with abdominal obesity) 8
Excluding Acute Illness
To ensure CRP elevation is not from acute infection/injury:
- Check temperature and screen for infection/injury symptoms 2
- Consider interferon gamma-induced protein-10 if available 2
- Extremely high CRP (>50 mg/L) strongly suggests acute process requiring immediate evaluation 2
Common Pitfalls to Avoid
- Do not dismiss GGT >100 U/L as insignificant—this level warrants fibrosis assessment regardless of other factors 1
- Do not assume normal ALT/AST excludes cirrhosis—the AST:ALT ratio remains useful even when both are normal 1
- Do not overlook treatable autoimmune liver disease—autoantibodies and immunoglobulins may be normal in some cases 1
- Do not automatically exclude participants with CRP >10 mg/L from consideration—this may represent chronic elevation from metabolic factors rather than acute illness 2
Follow-up Strategy
For patients not meeting immediate referral criteria:
- Repeat liver blood tests in 3 months to assess persistence
- Implement lifestyle modifications (weight loss, alcohol reduction, exercise)
- Optimize management of metabolic risk factors
- Consider repeat CRP to distinguish chronic elevation from transient acute phase response 2